Add to ORKG¤ Objectives: The primary objective of this study is to de-termine whether daily exit-site application of standardized antibacterial honey (Medihoney Antibacterial Wound Gel; Comvita, Te Puke, New Zealand) results in a reduced risk of catheter-associated infections in peritoneal dialysis (PD) patients compared with standard topical mupirocin prophy-laxis of nasal staphylococcal carriers
♦ Objective: We evaluated the effectiveness of local ap-plication of mupirocin ointment at the cathe...
A study was carried out to determine the possible ef-fectiveness of prophylactic application of mupi...
Background: A large proportion (15% to 50%) of the end-stage renal disease population are on periton...
Objectives: The primary objective of this study is to determine whether daily exit-site application ...
Background: The HONEYPOT study recently reported that daily exit-site application of antibacterial h...
Background: The HONEYPOT study is a multicenter, open-label, blinded-outcome, randomized controlled ...
The clinical usefulness of hemodialysis catheters is limited by increased infectious morbidity and m...
Infection is the Achilles heel of peritoneal dialysis. Exit site mupirocin prevents Staphylococcus a...
Prophylactic mupirocin for peritoneal catheter exit sites reduces exit site infection (ESI) risk but...
Access-related infections (ARIs), such as exit-site infections, tunnel infections, bacteremia, funge...
Peritoneal catheter exit-site and tunnel infections remain critical problems in patients undergoing ...
Background: Peritonitis still represents a common and major complication of peritoneal dialysis. The...
Introduction: Exit site infections (ESIs), the most common complication in peritoneal dialysis (PD),...
IntroductionPeritoneal dialysis (PD) is a widely used dialysis modality, which offers the advantage ...
label, blinded-outcome, randomized controlled trial designed to determine whether, compared with sta...
♦ Objective: We evaluated the effectiveness of local ap-plication of mupirocin ointment at the cathe...
A study was carried out to determine the possible ef-fectiveness of prophylactic application of mupi...
Background: A large proportion (15% to 50%) of the end-stage renal disease population are on periton...
Objectives: The primary objective of this study is to determine whether daily exit-site application ...
Background: The HONEYPOT study recently reported that daily exit-site application of antibacterial h...
Background: The HONEYPOT study is a multicenter, open-label, blinded-outcome, randomized controlled ...
The clinical usefulness of hemodialysis catheters is limited by increased infectious morbidity and m...
Infection is the Achilles heel of peritoneal dialysis. Exit site mupirocin prevents Staphylococcus a...
Prophylactic mupirocin for peritoneal catheter exit sites reduces exit site infection (ESI) risk but...
Access-related infections (ARIs), such as exit-site infections, tunnel infections, bacteremia, funge...
Peritoneal catheter exit-site and tunnel infections remain critical problems in patients undergoing ...
Background: Peritonitis still represents a common and major complication of peritoneal dialysis. The...
Introduction: Exit site infections (ESIs), the most common complication in peritoneal dialysis (PD),...
IntroductionPeritoneal dialysis (PD) is a widely used dialysis modality, which offers the advantage ...
label, blinded-outcome, randomized controlled trial designed to determine whether, compared with sta...
♦ Objective: We evaluated the effectiveness of local ap-plication of mupirocin ointment at the cathe...
A study was carried out to determine the possible ef-fectiveness of prophylactic application of mupi...
Background: A large proportion (15% to 50%) of the end-stage renal disease population are on periton...